- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Eisai introduces support program for Belviq
- Eisai launches educational resource for worker obesity management
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
WOODCLIFF LAKE, N.J. — Valeant Pharmaceuticals has bought rights to a drug used to treat skin cancer from Eisai, the companies said Thursday.
Valeant has bought the rights to Targretin (bexarotene) capsules and gel from Eisai for $65 million upfront, plus additional payments based on certain milestones. Under the deal, Eisai has transferred its regulatory approval application to Valeant, which will assume responsibilities for all regulatory obligations associated with the product in the United States. Eisai will retain rights to the drug outside the United States.
The drug is used to treat skin problems arising from a disease called cutaneous T-cell lymphoma, or CTCL, when at least one systemic therapy has not worked.